Please use this identifier to cite or link to this item:
|Title:||Therapeutic angiogenesis by transplantation of human embryonic stem cell-derived CD133+ endothelial progenitor cells for cardiac repair|
|Authors:||Rufaihah, A.J. |
Embryonic stem cells
|Source:||Rufaihah, A.J., Haider, H.K., Heng, B.C., Ye, L., Tan, R.S., Toh, W.S., Tian, X.F., Sim, E.K.-W., Cao, T. (2010-03). Therapeutic angiogenesis by transplantation of human embryonic stem cell-derived CD133+ endothelial progenitor cells for cardiac repair. Regenerative Medicine 5 (2) : 231-244. ScholarBank@NUS Repository. https://doi.org/10.2217/rme.09.83|
|Abstract:||Objective: This study aim to enhance endothelial differentiation of human embryonic stem cells (hESCs) by transduction of an adenovirus (Ad) vector expressing hVEGF165 gene (Ad-hVEGF165). Purified hESC-derived CD133+ endothelial progenitors were transplanted into a rat myocardial infarct model to assess their ability to contribute to heart regeneration. Methods: Optimal transduction efficiency with high cell viability was achieved by exposing differentiating hESCs to viral particles at a ratio of 1:500 for 4 h on three consecutive days. Results: Reverse transcription-PCR analysis showed positive upregulation of VEGF, Ang-1, Flt-1, Tie-2, CD34, CD31, CD133 and Flk-1 gene expression in Ad-hVEGF165-transduced cells. Additionally, flow cytometric analysis of CD133, a cell surface marker, revealed an approximately fivefold increase of CD133 marker expression in Ad-hVEGF 165-transduced cells compared with the nontransduced control. Within a rat myocardial infarct model, transplanted CD133+ endothelial progenitor cells survived and participated, both actively and passively, in the regeneration of the infarcted myocardium, as seen by an approximately threefold increase in mature blood vessel density (13.62 ± 1.56 vs 5.11 ± 1.23; p < 0.01), as well as significantly reduced infarct size (28% ± 8.2% vs 76% ± 5.6%; p < 0.01) in the transplanted group compared with the culture medium-injected control. There was significant improvement in heart function 6 weeks post-transplantation, as confirmed by regional blood-flow analysis (1.72 ± 0.612 ml/min/g vs 0.8 ± 0.256 ml/min/g; p < 0.05), as well as echocardiography assessment of left ventricular ejection fraction (60.855% ± 7.7% vs 38.22 ± 8.6%; p < 0.05) and fractional shortening (38.63% ± 9.3% vs 25.2% ± 7.11%; p < 0.05). Conclusion: hESC-derived CD133+ endothelial progenitor cells can be utilized to regenerate the infarcted heart. © 2010 Future Medicine Ltd.|
|Source Title:||Regenerative Medicine|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Jan 15, 2018
WEB OF SCIENCETM
checked on Jan 15, 2018
checked on Jan 12, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.